Intra-Individual Comparisons of [18F]fluorodeoxyglucose and Prostate-Specific Membrane Antigen Positron Emission Tomography in Prostate Cancer Patients Across Different Disease States: New Insights into Disease Heterogeneity
Open Access
Abstract
Background/Objectives: Prostate-specific membrane antigen (PSMA) PET/CT is more accurate than CT and bone scans for staging intermediate and high-risk prostate cancer (PCa). Fluorodeoxyglucose (FDG) PET has improved disease characterisation in metastatic castrate-resistant PCa (mCRPCa) and indicates patients with a particularly poor prognosis. The aim of this study was to assess the benefits of both PSMA and FDG PET in PCa staging by the direct intra-individual comparison of PSMA and FDG uptake patterns. Methods: Patients who underwent both PSMA and FDG PET/CT from 2015 to 2020 at our institution were identified and included if they had a histological or clinical diagnosis of PCa. Medical records were reviewed for demographic information and clinical details (including PSA, previous treatment, and disease status). Imaging interpretation was based on reporting by experienced nuclear medicine physicians. Results: Sixteen patients were identified. In 11 men with localised or hormone-sensitive PCa, PSMA-avid and FDG-avid disease was seen in 64% (n = 7) and 9% (n = 1) of patients, respectively. FDG-avid disease was present in 60% of patients with mCRPCa (n = 3/5), all of whom showed PSMA uptake. Of note, one patient showed higher initial FDG uptake that progressed in size and uptake on PSMA PET over 12 months. Conclusions: FDG PET might be useful in the assessment of patients with high clinical suspicion of metastases (e.g., high PSA, symptoms) with negative PSMA PET, particularly in castrate-resistant PCa.Keywords
Funding Information
- Royal Brisbane and Women’s Hospital Foundation
This publication has 35 references indexed in Scilit:
- Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PETUrology Case Reports, 2021
- Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionClinical Genitourinary Cancer, 2019
- A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC)Molecular Imaging and Biology, 2019
- 68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?Clinical Genitourinary Cancer, 2018
- Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histologyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Targeting PSMA by radioligands in non-prostate disease—current status and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- The Diagnosis and Treatment of Prostate CancerJAMA, 2017
- Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitationsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJournal of Cellular Biochemistry, 2003